{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:40:41Z","timestamp":1779900041772,"version":"3.53.1"},"reference-count":55,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Laryngoscope"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Ocular surface reactions (OSR) have been associated with dupilumab for atopic dermatitis (AD) treatment. However, the association of dupilumab\u2010associated OSR (DA\u2010OSR) for nasal polyps (CRSwNP) treatment has not been studied. We evaluated DA\u2010OSR for CRSwNP treatment using the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS was queried for any general ocular reactions (DA\u2010GOR) from 2019Q1 to 2022Q4. DA\u2010OSR were subcategorized from DA\u2010GOR and compared between treatment groups (CRSwNP, asthma, AD). Logistic regression was used to predict DA\u2010OSR. Disproportionality analysis (DPA) of DA\u2010OSR was performed using OpenVigil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 60,198 total observations, of which 5344 were treated for CRSwNP. The prevalence of DA\u2010GOR and DA\u2010OSR was greatest for AD (15.3%, 7.8%), followed by CRSwNP (12.2%, 6.7%) and asthma (9.2%, 3.5%). The most commonly reported OSRs were dry eyes (35.9%), conjunctivitis (15.7%), and increased lacrimation (11.0%). The reported odds ratio (ROR) of CRSwNP\u2010treated DA\u2010OSR was 0.84 (0.73\u20130.97; p\u2009=\u20090.015), compared to 1.29 (1.20\u20131.40;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) for AD and 0.66 (0.59\u20130.73;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) for asthma. For CRSwNP treatment, the DA\u2010OSR ROR was 0.97 (0.90\u20131.03; p\u2009=\u20090.3) for men and 0.78 (0.73\u20130.83,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) for older adults (age\u2009&gt;\u200950). ROR in the DPA for DA\u2010OSR was 12.5 (12.2\u201312.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) for any indication and 0.58 (0.53\u20130.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) for CRSwNP treatment only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While there are limitations to FAERS, this study confirms the association between dupilumab and OSR for AD treatment, and does not support an association between dupilumab and OSR for CRSwNP treatment. Younger adults experience more DA\u2010OSR in CRSwNP treatment without a specific predilection for sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence<\/jats:title>\n                    <jats:p>\n                      IV\n                      <jats:italic>Laryngoscope<\/jats:italic>\n                      , 134:2602\u20132608, 2024\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/lary.31205","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T12:08:40Z","timestamp":1701432520000},"page":"2602-2608","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment"],"prefix":"10.1002","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9427-1914","authenticated-orcid":false,"given":"Austin R.","family":"Swisher","sequence":"first","affiliation":[{"name":"Riverside School of Medicine University of California  Riverside California U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-2685","authenticated-orcid":false,"given":"Rijul S.","family":"Kshirsagar","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery Kaiser Permanente  Redwood City California U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla Q.","family":"Vu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Kaiser Permanente  Union City California U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery Kaiser Permanente  Oakland California U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.12.021"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.063"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhino12.000"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1324"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.029"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13875"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.02.023"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31881-1"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(21)00097-7"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000519228"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.S258438"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2017.06.017"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13924"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3427"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0000000000002262"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2019.100550"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1533567"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.01.034"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2018.1553190"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.10.016"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01379-9"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31191-1"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.02.002"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17981"},{"key":"e_1_2_6_28_1","unstructured":"Center for Drug Evaluation and Research.Questions and answers on FDA's adverse event reporting system (FAERS).2023. Accessed August 25 2023.https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm."},{"key":"e_1_2_6_29_1","unstructured":"OpenVigil FDA v1.0.2.OpenVigil: open tools for data\u2010mining and analysis of pharmacovigilance data.2023. Accessed August 25 2023.https:\/\/openvigil.sourceforge.net."},{"key":"e_1_2_6_30_1","unstructured":"OpenFDA.Drug Adverse Event Overview.2023.https:\/\/open.fda.gov\/apis\/drug\/event."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157753"},{"key":"e_1_2_6_32_1","doi-asserted-by":"crossref","unstructured":"Food and Drug Administration USA.FDA Adverse Event Reporting System(FAERS) Public Dashboard.2023. Accessed August 25 2023.https:\/\/www.fda.gov\/drugs\/questions\u2010andanswers\u2010fdas\u2010adverse\u2010event\u2010reporting\u2010system\u2010faers\/fda\u2010adverse\u2010eventreporting\u2010system\u2010faers\u2010public\u2010dashboard.","DOI":"10.2174\/0113894501290296240327081624"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1875-5364(13)60035-7"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1799975"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01298-9"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin18.282"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29230"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22780"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13685"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2022.103615"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145561320964653"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1700366"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.031"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16348"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93750-3"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.003"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2690"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29992"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.01.043"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v15i3.7456"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-0191-9"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00441-z"}],"container-title":["The Laryngoscope"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.31205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/lary.31205","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lary.31205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:42:20Z","timestamp":1771378940000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lary.31205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/lary.31205"],"URL":"https:\/\/doi.org\/10.1002\/lary.31205","archive":["Portico"],"relation":{},"ISSN":["0023-852X","1531-4995"],"issn-type":[{"value":"0023-852X","type":"print"},{"value":"1531-4995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"2023-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}